More from the Company Monthly Newsletter March 2019
During the month of March, we continued our development and documentation work, participated in the 9th Annual Therapeutic Hypothermia Conference in Miami and presented at ABG Sundal Collier Introduce Investor Days in Stockholm.
The highlight of the month was the participation in The 9th Annual Therapeutic Hypothermia Targeted Temperatue Management and the Use of ECMO in Critical Care Event in Miami.
Most of the participants were researchers, medical doctors and nurses from the USA, but also from another 15 countries or so. It was an exceptionally wide-ranging program. Some of the topics that were discussed included:
• Temperature Management in Neurological and Neurosurgical ICU
• Perspectives on Temperature Management
• Therapeutic Hypothermia in Post-Cardiac Arrest
• Targeted Temperature Management in Nursing Care
• Clinical Studies Targeting Stroke
• Cooling Strategies in Unique Areas
• Current Advances in the Use of Therapeutic Hypothermia
The most interesting and exciting news was the fact that 1) One is conducting research within many new fields and indications to find scientific evidence for hypothermia. 2) One hypothesis is to, with the help of biomarkers, find each individual’s optimized temperature for cooling treatment. The hypothesis is based on the fact that each individual is unique and therefore one should individualize the cooling treatment accordingly in order to achieve the best clinical result for each individual.
We believe that QuickCool offers a unique solution that addresses many of the needs of conscious patients that were presented.
Read more by clicking on the following link below:
Quickcool AB also participated in the ABG Sundal Collier Introduce Investor Days in Stockholm. Some material from The 9th Annual Therapeutic Hypothermia Targeted Temperatue Management conference was included in the presentation. Unfortunately, the presentation is primarily in Swedish. Some slides from the conference in the US are in English. You may access this material by clicking on the following link:
Lastly, an interview from mid-March with Fredrik Radencrantz, CEO of QuickCool, may be found on YouTube (unfortunately, only in Swedish) by clicking on the link below:
https://www.youtube.com/watch?v=5sFEo3uASLs&feature=youtu.be
Follow us on LinkedIn. Additional information about QuickCool and our solution may be found on our homepage: http://www.quickcool.se/en/home.html
Kind regards,
Fredrik
Fredrik Radencrantz
CEO
QuickCool AB
Ideon Science Park
Beta 6, Scheelevägen 17 - SE-223 70 Lund - Sweden
E-mail: fredrik.radencrantz@quickcool.se Web: www.quickcool.se
Mobile +46 (0)73 834 1188
QuickCool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the QuickCool® SYSTEM. QuickCool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. QuickCool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se
Tags: